In Vitro effects of novel ruthenium complexes in Neospora caninum and Toxoplasma gondii tachyzoites

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5747-5754

  Barna, Fabienne ^a   Debache, Karim ^a   Vock, Carsten A ^b   Küster, Tatiana ^a   Hemphill, Andrew ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COCCIDIOSTATIC AGENT; RUTHENIUM COMPLEX;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LONG TERM EXPOSURE; NEOSPORA CANINUM; NONHUMAN; PRIORITY JOURNAL; TACHYZOITE; TOXOPLASMA GONDII; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT DURATION;

ANIMALS; CERCOPITHECUS AETHIOPS; COORDINATION COMPLEXES; FIBROBLASTS; HUMANS; INHIBITORY CONCENTRATION 50; LIFE CYCLE STAGES; MICROSCOPY, ELECTRON, TRANSMISSION; NEOSPORA; RUTHENIUM; TOXOPLASMA; VERO CELLS;

EID: 84885905318     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02446-12     Document Type: Article

References (63)

1. Reid AJ, Vermont SJ, Cotton JA, Harris D, Hill-Cawthorne GA, Könen-Waisman S, Latham SM, Mourier T, Norton R, Quail MA, Sanders M, Shanmugam D, Sohal A, Wasmuth JD, Brunk B, Grigg ME, Howard JC, Parkinson J, Roos DS, Trees AJ, Berriman M, Pain A, Wastling JM. 2012. Comparative genomics of the apicomplexan parasites Toxoplasma gondii and Neospora caninum: coccidia differing in host range and transmission strategy. PLoS Pathog. 8:e1002567. doi:10.1371/journal.ppat .1002567.
2. Hemphill A, Vonlaufen N, Naguleswaran A. 2006. Cellular and immunological basis of the host-parasite relationship during infection with Neospora caninum. Parasitology 133:261-278.
3. Innes EA, Vermeulen AN. 2006. Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora. Parasitology 133(Suppl):S145-S168.
4. Dubey JP, Schares G, Ortega-Mora LM. 2007. Epidemiology and control of neosporosis and Neospora caninum. Clin. Microbiol. Rev. 20:323-367.
5. Monney T, Debache K, Hemphill A. 2011. Vaccines against a major cause of abortion in cattle, Neospora caninum infection. Animals 1:306-325.
6. Reichel MP, Ayanegui-Alcérrecac M, Gondim LF, Ellis JT. 2013. What is the global economic impact of Neospora caninum in cattle -the billion dollar question. Int. J. Parasitol. 43:133-142.
7. Saadatnia G, Golkar M. 2012. A review on human toxoplasmosis. Scand. J. Infect. Dis. 44:805-814.
8. Kortagere S. 2012. Screening for small molecule inhibitors of Toxoplasma gondii. Expert Opin. Drug Discov. 7:1193-1206.
9. Röse I. 1997. Morphology and diagnostics of human toxoplasmosis. Gen. Diagn. Pathol. 142:257-270.
10. Dedicoat M, Livesley N. 2006. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst. Rev. 19:CD005420. doi:10.1002/14651858 .CD005420.pub2.
11. Khalili H, Soudbakhsh A, Talasaz AH. 2011. Severe hepatotoxicity and probable hepatorenal syndrome associated with sulfadiazine. Am. J. Health Syst. Pharm. 68:888-892.
12. Häsler B, Regula G, Stärk KD, Sager H, Gottstein B, Reist M. 2006. Financial analysis of various strategies for the control of Neospora caninum in dairy cattle in Switzerland. Prev. Vet. Med. 77:230-253.
13. Häsler B, Stärk KD, Sager H, Gottstein B, Reist M. 2006. Simulating the impact of four control strategies on the population dynamics of Neospora caninum infection in Swiss dairy cattle. Prev. Vet. Med. 77:254-283.
14. Lindsay DS, Dubey JP. 1990. Effects of sulfadiazine and amprolium on Neospora caninum (Protozoa: Apicomplexa) infections in mice. J. Parasitol. 76:177-179.
15. Lindsay DS, Dubey JP. 1989. Evaluation of anti-coccidial drugs' inhibition of Neospora caninum development in cell cultures. J. Parasitol. 75: 990-992.
16. Lindsay DS, Rippey NS, Cole RA, Parsons LC, Dubey JP, Tidwell RR, Blagburn BL. 1994. Examination of the activities of 43 chemotherapeutic agents against Neospora caninum tachyzoites in cultured cells. Am. J. Vet. Res. 55:976-981.
17. Ammann P, Waldvogel A, Breyer I, Esposito M, Müller N, Gottstein B. 2004. The role of B-and T-cell immunity in toltrazuril-treated C57BL/6 WT, microMT and nude mice experimentally infected with Neospora caninum. Parasitol. Res. 93:178-187.
18. Gottstein B, Eperon S, Dai WJ, Cannas A, Hemphill A, Greif G. 2001. Efficacy of toltrazuril and ponazuril against experimental Neospora caninum infection in mice. Parasitol. Res. 87:43-48.
19. Gottstein B, Razmi GR, Ammann P, Sager H, Müller N. 2005. Toltrazuril treatment to control diaplacental Neospora caninum transmission in experimentally infected pregnant mice. Parasitology 130:41-48.
20. Debache K, Hemphill A. 2012. Effects of miltefosine treatment in fibroblast cell cultures and in mice experimentally infected with Neospora caninum tachyzoites. Parasitology 139:934-944.
21. Wang MZ, Zhu X, Srivastava A, Liu Q, Sweat JM, Pandharkar T, Stephens CE, Riccio E, Parman T, Munde M, Mandal S, Madhubala R, Tidwell RR, Wilson WD, Boykin DW, Hall JE, Kyle DE, Werbovetz KA. 2010. Novel arylimidamides for treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 54:2507-2516.
22. Debache K, Guionaud C, Kropf C, Boykin D, Stephens CE, Hemphill A. 2011. Experimental treatment of Neospora caninum-infected mice with the arylimidamide DB750 and the thiazolide nitazoxanide. Exp. Parasitol. 129:95-100.
23. Schorer M, Debache K, Barna F, Monney T, Müller J, Boykin D, Stephens CE, Hemphill A. 2012. Di-cationic arylimidamides act against Neospora caninum tachyzoites by interference in membrane structure and nucleolar integrity and are active against challenge infection in mice. Int. J. Parasitol. Drugs Drug Resist. 2:109-120.
24. Kropf C, Debache K, Rampa C, Barna F, Schorer M, Stephens CE, Ismail MA, Boykin DW, Hemphill A. 2012. The adaptive potential of a survival artist: characterization of the in vitro interactions of Toxoplasma gondii tachyzoites with di-cationic compounds in human fibroblast cell cultures. Parasitology. 139:208-220.
25. Schwietert CW, McCue JP. 1999. Coordination compounds in medicinal chemistry. Coord. Chem. Rev. 184:67-89.
26. Bruijnincx PCA, Sadler PJ. 2008. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol. 12:197-206.
27. Gasser G, Ott I, Metzler-Nolte N. 2011. Organometallic anticancer compounds. J. Med. Chem. 54:3-25.
28. Garbutcheon-Singh KB, Grant MP, Harper BW, Krause-Heuer AM, Manohar M, Orkey N, Aldrich-Wright Jr. 2011. Transition metal based anticancer drugs. Curr. Top. Med. Chem. 11:521-542.
29. Ang WH, Casini A, Sava G, Dyson PJ. 2011. Organometallic rutheniumbased antitumor compounds with novel modes of action. J. Organomet. Chem. 696:989-998.
30. Komeda S, Casini A. 2012. Next-generation anticancer metallodrugs. Curr. Top. Med. Chem. 12:219-235.
31. Rosenberg B, Vancamp L, Krigas T. 1965. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698-699.
32. Kostova I. 2006. Ruthenium complexes as anticancer agents. Curr. Med. Chem. 13:1085-1107.
33. Peacock AF, Sadler PJ. 2008. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. Chem. Asian J. 3:1890-1899.
34. Hartinger CG, Dyson PJ. 2009. Bioorganometallic chemistry -from teaching paradigms to medicinal applications. Chem. Soc. Rev. 38:391-401.
35. Levina A, Mitra A, Lay PA. 2009. Recent developments in ruthenium anticancer drugs. Metallomics 1:458-470.
36. Bergamo A, Sava G. 2011. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Trans. 40:7817-7823.
37. Beckford FA, Thessing J, Shaloski M, Mbarushimana PC, Brock A, Didion J, Woods J, Gonzalez-Sarrías A, Seeram NP. 2011. Synthesis and characterization of mixed-ligand diimine-piperonal thiosemicarbazone complexes of ruthenium(II): biophysical investigations and biological evaluation as anticancer and antibacterial agents. J. Mol. Struct. 992:39 -47.
38. Donnici CL, Araújo MG, Oliveira HS, Moreira DR, Pereira VR, de Assis Souza M, de Castro MC, Leite AC. 2009. Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: synthesis, biological characterization and structure-activity relationships. Bioorg. Med. Chem. 17:5038-5043.
39. Otero L, Aguirre G, Boiani L, Denicola A, Rigol C, Olea-Azar C, Maya JD, Morello A, González M, Gambino D, Cerecetto H. 2006. Nitrofurylsemicarbazone rhenium and ruthenium complexes as anti-trypanosomal agents. Eur. J. Med. Chem. 41:1231-1239.
40. Beckford F, Dourth D, Shaloski M, Didion J, Thessing J, Woods J, Crowell V, Gerasimchuk N, Gonzalez-Sarrias A, Seeram NP. 2011. Half-sandwich ruthenium arene complexes with thiosemicarbazones: synthesis and biological evaluation of [(-6-p-cymene)Ru(piperonal thiosemicarbazones) Cl]Cl complexes. J. Inorg. Biochem. 105:1019-1029.
41. Sathya N, Raja G, Priya NP, Jayabalakrishnan C. 2010. Ruthenium(II) complexes incorporating tridentate Schiff base ligands: synthesis, spectroscopic, redox, catalytic and biological properties. Appl. Organomet. Chem. 24:366-373.
42. Silva JJ, Guedes PM, Zottis A, Balliano TL, Silva FO, Lopes LG, Ellena J, Oliva G, Andricopulo AD, Franco DW, Silva JS. 2010. Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity. Br. J. Pharmacol. 160:260-269.
43. Silva JJ, Pavanelli WR, Pereira JC, Silva JS, Franco DW. 2009. Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors. Antimicrob. Agents Chemother. 53:4414 -4421.
44. Biot C, Nosten F, Fraisse L, Ter-Minassian D, Khalife J, Dive D. 2011. The antimalarial ferroquine: from bench to clinic. Parasite 18:207-214.
45. Sannella AR, Casini A, Gabbiani C, Messori L, Bilia AR, Vincieri FF, Majori G, Severini C. 2008. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett. 582: 844-847.
46. Caroli A, Simeoni S, Lepore R, Tramontano A, Via A. 2012. Investigation of a potential mechanism for the inhibition of SmTGR by auranofin and its implications for Plasmodium falciparum inhibition. Biochem. Biophys. Res. Commun. 417:576-581.
47. Rademaker-Lakhai JM, Van den Bongard D, Pluim D, Beijnen JH, Schellens JH. 2004. A phase I and pharmacological study with imidazolium-trans-DMSO- imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res. 10:3717-3727.
48. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK. 2006. From bench to bedside -preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1Hindazole) ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem. 100:891-904.
49. Lentz F, Drescher A, Lindauer A, Henke M, Hilger RA, Hartinger CG, Scheulen ME, Dittrich C, Keppler BK, Jaehde U. 2009. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anticancer Drugs 20:97-103.
50. Küster T, Lense N, Barna F, Hemphill A, Kindermann MK, Heinicke JW, Vock CA. 2012. A new promising application for highly cytotoxic metal compounds: 6-Arene ruthenium(II) phosphite complexes for the treatment of alveolar echinococcosis. J. Med. Chem. 55:4178-4188.
51. Lalrempuia R, Kollipara MR, Carroll PJ, Yap GPA, Kreisel KA. 2005. Synthesis and characterization of cyano-bridged homo and hetero bimetallic complexes containing h5-and h6-cyclic hydrocarbons. J. Organomet. Chem. 690:3990-3996.
52. Zimmer C, Hafner M, Zender M, Ammann D, Hartmann RW, Vock CA. 2011. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2). Bioorg. Med. Chem. Lett. 21:186-190.
53. Hille UE, Zimmer C, Vock CA, Hartmann RW. 2011. First selective CYP11B1 inhibitors for the treatment of cortisol-dependent diseases. ACS Med. Chem. Lett. 2:2-6.
54. Zhang C, Ding Z, Suhaimi NAM, Kng AL, Zhang Y, Zhuo L. 2009. A class of imidazolium salts is antioxidative and anti-fibrotic in hepatic stellate cells. Free Radic. Res. 43:899-912.
55. Gopalan B, Ke Z, Zhang C, Kng Y, Suhaimi NAM, Riduan SN, Zhang Y, Zhuo L. 2011. Metal-free imidazolium salts inhibit the growth of hepatocellular carcinoma in a mouse model. Lab. Invest. 91:744-751.
56. Hintermann L. 2007. Expedient syntheses of the N-heterocyclic carbene precursor imidazolium salts IPr.HCl, IMes.HCl and IXy.HCl. Beilstein J. Org. Chem. 3:22. doi:10.1186/1860-5397-3-22.
57. McFadden DC, Seeber F, Boothroyd JC. 1997. Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob. Agents Chemother. 41:1849-1853.
58. Puckett CA, Barton JK. 2007. Methods to explore cellular uptake of ruthenium complexes J. Am. Chem. Soc. 129:46-47.
59. Leepin A, Stüdli A, Brun R, Stephens CE, Boykin DW, Hemphill A. 2008. Host cells participate in the in vitro effects of novel diamidine analogues against tachyzoites of the intracellular apicomplexan parasites Neospora caninum and Toxoplasma gondii. Antimicrob. Agents Chemother. 52:1999-2008.
60. Scolaro C, Chaplin AB, Hartinger CG, Bergamo A, Cocchietto M, Keppler BK, Sava G, Dyson PJ. 2007. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans. 43:5065-5072.
61. Ravera M, Baracco S, Cassino C, Colangelo D, Bagni G, Sava G, Osella D. 2004. Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases. J. Inorg. Biochem. 98:984-990.
62. Casini A, Gabbiani C, Sorrentino F, Rigobello MP, Bindoli A, Geldbach TJ, Marrone A, Re N, Hartinger CG, Dyson PJ, Messori L. 2008. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J. Med. Chem. 51:6773-6781.
63. Klinkert MQ, Heussler V. 2006. The use of anticancer drugs in antiparasitic chemotherapy. Mini Rev. Med. Chem. 6:131-143.